Publicação científica trimestral do CREMERJ - volume 2 - número 2 - 2023

85 Med. Ciên. e Arte , Rio de Janeiro, v.2, n.2, p.77-86, abr-jun 2023 Tromboembolismo venoso no climatério André Luiz Malavasi Longo de Oliveira et al. REFERÊNCIAS 1. Canonico M. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Maturitas. 2015;82(3):304-7. 2. Oger E. Incidence of Venous Thromboembolism: A Community-based Study in Western France. Thromb Haemost. 2000;83(05):657-60. 3. Scarabin P-Y. Hormone therapy and venous thromboembolism among postmenopausal women. Front Horm Res. 2014;43:21-32. 4. Anderson FA, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933-8. 5. Olié V, et al. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol. 2010;17(5):457-63. 6. Royal College of Obstetricians & Gynaecologists. Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management [Green-top Guideline No. 37b]; 2015 [acesso em 22 Jun 2018]. Disponível em: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37b.pdf. 7. Marjoribanks J, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1:CD004143. 8. Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. 9. Canonico M, et al. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas. 2011;70(4):354-60. 10. Canonico M, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227-31. 11. Hulley S. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. JAMA. 1998;280(7):605. 12. Høibraaten E, et al. Increased Risk of Recurrent Venous Thromboembolism during Hormone Replacement Therapy. Thromb Haemost. 2000;84(12):961-7. 13. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR: Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292:1573-1580. 14. Curb JD, et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Arch Intern Med. 2006;166(7):772. 15. Vickers MR, et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomized controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007;335(7613):239. 16. Daly E, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348(9033):977-80. 17. Høibraaten E, et al. Hormone replacement therapy with estradiol and risk of venous thromboembolism: a population-based case-control study. Thromb Haemost. 1999;82(4):1218-21. 18. Gutthann SP, et al. Hormone replacement therapy and risk of venous thromboembolism: population- based case-control study. Maturitas. 1997;314(7083):293. 19. Douketis JD, et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost. 2005;3(5):943-8. 20. Scarabin P-Y, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362(9382):428-32.